J&J, Centocor Complete Merger

Johnson & Johnson (New Brunswick, NJ) and Centocor Inc. (Malvern, PA) have completed their previously announced $4.9 billion merger. The deal went through after Centocor shareholders voted to approve the merger agreement.

In accordance with Pennsylvania law, a Johnson & Johnson subsidiary has been merged with and into Centocor Inc. Centocor will retain its name and will operate as a direct, wholly owned subsidiary of Johnson & Johnson.

Under terms of the agreement, holders of Centocor common stock will receive 0.6390 of a share of Johnson & Johnson common stock for each share of Centocor common stock that they own, and cash will be provided for fractional shares.

Centocor Inc. develops monoclonal antibody technology and acute vascular care and immunology products.

Johnson & Johnson is a global health care products manufacturer.

For more information: Johnson & Johnson, 1 Johnson & Johnson Plaza, New Brunswick, NJ 08933. Tel: 732-524-0400. Fax: 732-524-3300.

Edited by Jim Pomager